Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Barth, D.
Small Platelets and Prognosis in Patients with Colorectal Cancer
Humanmedizin; [ Diplomarbeit ] Medical University of Graz; 2019. pp. 78
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Gerger Armin
- Posch Florian
- Stotz Michael
- Altmetrics:
- Abstract:
- Background: The role of mean platelet volume (MPV) as a predictor of outcomes in various cancer entities including colorectal cancer (CRC) has already been analysed. However, data on the prognostic and predictive value of small platelets in CRC over multiple lines of systemic therapy are still missing. Material and Methods: In this retrospective single-centre cohort study, 690 patients with UICC stage II, III or IV CRC receiving adjuvant and/or palliative chemotherapy were included. Primary endpoints in the adjuvant setting, palliative setting and best supportive care (BSC) setting were 3-year recurrence- free survival (RFS), 6-months progression- free survival (PFS), and 6 months overall survival (OS), respectively. Kaplan-Meier estimators, log-rank tests, and uni- and multivariable Cox models were used to analyse RFS, PFS and OS. A cut-off defining patients with low MPV was chosen empirically at the 25th percentile of the MPV distribution in the respective treatment setting. Results: Three-year RFS was 76%. Median 6-month PFS estimates in 1st, 2nd, and 3rd line therapy were 59%, 37%, and 27%, respectively, and median 6-month OS in BSC was 31%. Small platelets as indicated by low MPV did not predict for shorter RFS. Also, in the first 3 palliative treatment lines we did not observe a consistent association between low MPV and decreased 6-month PFS. In the BSC setting, patients with low MPV had numerically but not significantly shorter OS. Higher MPV levels did not consistently predict for ORR or DCR across the first 3 palliative treatment lines. Conclusion: This study shows that the platelet volume does not predict CRC outcome, and thus is hardly useful for influencing clinical decision-making.